# EDGAR Filing Document

**Accession Number:** 0001022899
**File Stem:** 0001493152-25-013851
**Filing Date:** 2025-9
**Character Count:** 6771
**Document Hash:** 48d16145818380165759d1de92ab92b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-013851.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0001493152-25-013851

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20250515

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250917

**DATE AS OF CHANGE**: 20250917

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protagenic Therapeutics, Inc.\new
- **CENTRAL INDEX KEY:** 0001022899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061390025
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12555
- **FILM NUMBER:** 251319277

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 994-8200

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Atrinsic, Inc.
- **DATE OF NAME CHANGE:** 20090630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEW MOTION, INC.
- **DATE OF NAME CHANGE:** 20070504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MPLC, Inc.
- **DATE OF NAME CHANGE:** 20050608

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**(Amendment No. 2)**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

---

| | |
|:---|:---|
| **Date of Report (Date of Earliest Event Reported):** | **May 15, 2025** |

---

---

| |
|:---|
| **PROTAGENIC THERAPEUTICS, INC.** |
| (Exact name of Company as specified in its charter) |

---

<u>Delaware</u> <u>001-12555</u> <u>06-1390025</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

<u>149 Fifth Avenue, Suite 500, New York, NY</u> <u>10010</u> <br> (Address of principal executive offices) (Zip Code)

<u>212-994-8200</u> <br> (Company's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered |
| Common Stock | PTIX | Nasdaq |
| Common Stock Warrants | PTIXW | Nasdaq |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Explanatory Note**

As previously reported, on May 19, 2025, Protagenic Therapeutics, Inc. (the "Company") filed a Current Report on Form 8-K (the "Original Form 8-K") reporting that on May 15, 2025, the Company entered into the Share Exchange Agreement (the "Exchange Agreement") with Alterola Biotech Inc., a Nevada corporation ("Alterola"), EMC2 Capital LLC, a Wyoming limited liability corporation ("EMC2"), the preferred stockholders of Phytanix set forth on Schedule A thereto (the "Preferred Stockholders") and Colin Stott, as "Seller's Representative (as defined therein), pursuant to which the Company acquired 100% of the issued and outstanding common shares of Phytanix Bio, a Nevada corporation ("Phytanix") (such transaction, the "Combination"). Prior to the Combination, Alterola and EMC2 collectively owned 100% of the issued and outstanding shares of the common shares of Phytanix (the "Shares"), and the Preferred Stockholders collectively owned 100% of the issued and outstanding shares of Series A convertible preferred shares of Phytanix (the "Preferred Shares").

On August 28, 2025, the "Company" filed a Current Report on Form 8-K/A (together with the Original Form 8-K, the "Original Form 8-K/A") to include the financial statements and unaudited pro form financial information required by Items 9.01(a) and (b) of Form 8-K, respectively, which were not included in the Original Form 8-K pursuant to Items 9.01(a)(3) and (b)(2) of Form 8-K.

This Current Report on Form 8-K/A, amends Item 9.01 of the Original Form 8-K/A to update Exhibit 23.1. No other changes have been made to the Original Form 8-K/A.

**Item 9.01 Financial Statements and Exhibits.**

Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 23.1 | [Consent of GreenGrowth CPAs Inc.](ex23-1.htm)<br>|
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PROTAGENIC THERAPEUTICS, INC. | PROTAGENIC THERAPEUTICS, INC. |
| Date: September 17, 2025 | By: | */s/ Alexander K. Arrow* |
|  | Name: | Alexander K. Arrow |
|  | Title: | Chief Financial Officer |

---

## Exhibit 23.1

**Exhibit 23.1**

To the Board of Directors and Shareholders of Protagenic Therapeutics, Inc.

We consent to the inclusion in the Form 8-K/A incorporated by reference in the Form S-3/A Registration Statement (Ref. No. 333-280244) of Protagenic Therapeutics, Inc. of our report dated August 27, 2025, relating to our audit of the consolidated balance sheet of Phytanix Bio, Inc. and its subsidiaries as of March 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, changes in stockholders' deficit, and cash flows for the periods then ended, and the related notes.

![P11#yIS1](ex23-1_002.jpg)

September 16, 2025.

We served as the Company's auditor since 2024

Los Angeles, California

PCAOB ID Number 6580